Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Sex-linked Disorders01:43

Sex-linked Disorders

93.7K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
93.7K
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

68
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
68
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

25
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
25

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liver Involvement in POLG Disease-a Multicentre Cohort Study of 202 Patients.

Journal of inherited metabolic disease·2025
Same author

Type 1 spinal muscular atrophy treated with nusinersen in Norway, a five-year follow-up.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2024
Same author

Epidemiology and natural history of POLG disease in Norway: a nationwide cohort study.

Annals of clinical and translational neurology·2024
Same author

Status epilepticus in POLG disease: a large multinational study.

Journal of neurology·2024
Same author

[Correction: Myotonic dystrophy type 1 – a multiorgan disorder].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2024
Same author

Myotonic dystrophy type 1 - a multiorgan disorder.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2024
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Correction: Management of acute epistaxis.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

A woman in her 70s with chest pain and elevated troponin T levels.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

More systematic follow-up after childbirth.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.7K

Duchenne muscular dystrophy.

Ellen J Annexstad1, Inger Lund-Petersen2, Magnhild Rasmussen3

  • 1Kompetansesenter for medfødte muskelsykdommer Oslo universitetssykehus og Barneavdelingen Sykehuset Østfold Fredrikstad.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|August 7, 2014
PubMed
Summary
This summary is machine-generated.

Duchenne muscular dystrophy (DMD) treatments have improved patient outcomes. Ongoing research into causal therapies offers hope for the future, alongside comprehensive care for affected children and adults.

More Related Videos

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.7K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

5.5K

Related Experiment Videos

Last Updated: Apr 26, 2026

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.7K
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.7K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

5.5K

Area of Science:

  • Pediatric Neurology
  • Genetics and Molecular Biology
  • Rehabilitation Medicine

Background:

  • Duchenne muscular dystrophy (DMD) is a severe childhood-onset neuromuscular disorder.
  • Recent advancements have significantly enhanced quality of life and life expectancy for DMD patients.
  • Understanding DMD's progression and management is crucial for affected children.

Purpose of the Study:

  • To summarize key characteristics of Duchenne muscular dystrophy.
  • To review current treatment strategies for DMD.
  • To explore emerging therapeutic options for DMD.

Main Methods:

  • Literature review utilizing PubMed.
  • Analysis of current international clinical guidelines.
  • Incorporation of clinical expertise in Duchenne muscular dystrophy management.

Main Results:

  • Interdisciplinary team monitoring is fundamental to DMD care.
  • Glucocorticoid therapy can temporarily slow disease progression and improve motor function.
  • Management must address potential side effects, cognitive/neuropsychiatric issues, and organ-specific failures (respiratory/cardiac).

Conclusions:

  • Improved treatments and longevity present new challenges for DMD patients and families.
  • Comprehensive, lifelong follow-up is essential, including the transition to adult care.
  • The evolving landscape of DMD care necessitates adaptable support services.